BRCAOmics Test

The BRCAOmics Test is an innovative tool in genetic testing for BRCA gene mutations, designed to identify alterations in the BRCA1 and BRCA2 genes—crucial players in DNA repair and genomic stability. Mutations in these genes significantly increase the risk of developing cancers such as breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Early identification of these mutations empowers individuals to take proactive measures, including regular screenings, preventive strategies, and targeted treatments, thereby bridging the gap between genetic risk and actionable health strategies.

Looking for more? We offer competitive pricing—contact us for the best deals!

Quantity

Breast Cancer DNA Test

The BRCAOmics Test is an innovative tool in genetic testing for BRCA gene mutations, designed to identify alterations in the BRCA1 and BRCA2 genes—crucial players in DNA repair and genomic stability. Mutations in these genes significantly increase the risk of developing cancers such as breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Early identification of these mutations empowers individuals to take proactive measures, including regular screenings, preventive strategies, and targeted treatments, thereby bridging the gap between genetic risk and actionable health strategies.

1. Who Should Take the BRCAOmics Test?

The BRCAOmics Test is highly recommended for individuals who:

  • Have a Family History of Cancer: If immediate family members have been diagnosed with breast, ovarian, pancreatic, or prostate cancer, understanding inherited risks can guide preventive actions.
  • Are Cancer Survivors: Those diagnosed with cancer may benefit from understanding if a BRCA mutation contributed to their condition, which could guide further treatment options or assess risks for other cancers.
  • Want Comprehensive Cancer Risk Insights: This test not only screens for breast cancer risk but also evaluates risks for other cancers associated with BRCA mutations.
  • Women Seeking Early Detection: The test supports breast cancer genetic testing by identifying BRCA mutations early, enabling timely screenings like mammograms or preventive surgeries.
  • Have Relatives with BRCA Mutations: For families where a known mutation exists, this test can determine if others carry the same risk.
2. Why Is This Test Important?

The BRCAOmics Test stands at the forefront of genetic testing for ovarian cancer and other BRCA-related cancers. 

Here’s why it matters:

  • Early Detection Saves Lives: Identifying mutations in BRCA1 and BRCA2 genes before cancer develops enables individuals to take timely preventive actions, including enhanced surveillance or risk-reducing measures.(5)
  • Comprehensive Cancer Risk Assessment: Beyond breast cancer, this test assesses risks for ovarian, pancreatic, and prostate cancers, providing a full spectrum of insights into genetic predispositions.(6)
  • Personalized Prevention Strategies: Tailored recommendations based on genetic findings help reduce cancer risk through preventive surgeries, lifestyle changes, or targeted screenings.(7)
  • Guides Treatment Plans: For those diagnosed with cancer, knowing their genetic makeup allows for targeted treatments like PARP inhibitors for BRCA mutation-related cancers.(8)
  • Family Health Awareness: Test results can also guide relatives in understanding their own genetic risks.(9)
  • Support Through Genetic Counseling: Our test includes access to expert counselors to help interpret results and plan the next steps confidently.(10)

Genetic Insight

General Population Estimates: Mutations in BRCA1 (0.7%) and BRCA2 (1.3%) were identified in a population-based study of 1,220 breast cancer cases, with penetrance by age 80 estimated at 48% and 74%, respectively. Combined ovarian cancer risk was 22%, and BRCA mutations accounted for 17% of familial breast cancer risk. These findings suggest that BRCA mutations are rare and contribute to a small fraction of breast cancer cases(1)(3)

Breast Cancer Patients: Among women diagnosed with breast cancer:

A study reported that 5.9% of women diagnosed before age 36 carried BRCA mutations, with 3.5% in BRCA1 and 2.4% in BRCA2.(2)

In Indian cohort, the prevalence of pathogenic BRCA mutations was found to be 16.6% among unselected consecutive breast cancer patients, which is notably higher than some previous estimates.(1)

Ovarian Cancer Patients: In a cohort of ovarian cancer patients, 29.8% were identified as carriers of BRCA mutations, with a predominance of BRCA1 mutations (75.8%) compared to BRCA2 (24.2%).(4)

3. DrOmics BRCAOmics Test for Genetic Cancer Risk

DrOmics Labs sets a new standard in genetic testing with its BRCAOmics Test, offering comprehensive cancer risk analysis for breast, ovarian, and prostate cancers. Utilizing cutting-edge sequencing technology, the test ensures precise, reliable results supported by genetic counseling to help individuals understand their risks and plan proactive measures. With tailored recommendations for preventive care, lifestyle adjustments, and enhanced surveillance, BRCAOmics is grounded in scientific and clinical validity, adhering to globally recognized databases like BRCAIndica, gnomAD, and ClinVar.

4. How Does This Work?

The process of undergoing the BRCAOmics Test is simple, efficient, and designed with patient comfort in mind:

  1. Sample Collection: A non-invasive saliva or cheek swab sample is collected.
  2. State-of-the-Art Lab Analysis: The sample undergoes rigorous analysis to detect mutations in the BRCA1 and BRCA2 genes.
  3. Detailed Reporting: You receive a comprehensive report detailing any genetic mutations, associated cancer risks, and recommended preventive or treatment measures.
  4. Expert Consultation: Genetic counselors review your results with you, offering personalized guidance and action plans.

Reviews

There are no reviews yet.

Be the first to review “BRCAOmics Test”

Your email address will not be published. Required fields are marked *

BRCAOmics Test

Bitbucket
Call Now Button